This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ASCO presentation: Phase II studies of PX-866 in solid tumors.
What we know already: Phase I trials showed PX-866 to be well tolerated with some evidence of anti-cancer activity. Oncothyreon is conducting phase II studies of PX-866 in combination with other drugs in non-small cell lung cancer, glioblastoma, prostate cancer, colon cancer and head-and-neck cancer.
Key questions: These studies are expected to complete patient enrollment by the end of the year. Oncothyreon is expected to present interim results from one or more of these trials at ASCO.
>>To see these stocks in action, visit the
7 Cancer Drug Stocks to Know Right Now portfolio on Stockpickr.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Twitter and become a fan on